The effects of acute renal failure on drug metabolism

Bibliography

• Fliser D, Laville M, Covic A, et al. A European Renal Best Practice (ERBP) position statement on the Kidney Disease Improving Global Outcomes (KDIGO) clinical practice guidelines on acute kidney injury: part 1: definitions, conservative management and contrast-induced nephropathy. Nephrol Dial transplant 2012;27(12):4263-72
   PubMed Web of Science ®Google Scholar
• Kellum J, Lameire N; Group ftKAGW. Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (Part 1). Crit Care 2013;17(1):204
   PubMed Web of Science ®Google Scholar
• Mehta RL, Kellum JA, Shah SV, et al. Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11(2):R31
   PubMed Web of Science ®Google Scholar
• Bellomo R, Ronco C, Kellum J, et al. Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R12
   PubMed Web of Science ®Google Scholar
• Tian J, Barrantes F, Amoateng-Adjepong Y, Manthous CA. Rapid reversal of acute kidney injury and hospital outcomes: a retrospective cohort study. Am J Kidney Dis 2009;53(6):974-81
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, George C, Bellomo R. Changes in the incidence and outcome for early acute kidney injury in a cohort of Australian intensive care units. Crit Care 2007;11(3):R68
   PubMedGoogle Scholar
• Ostermann M, Chang RW. Acute kidney injury in the intensive care unit according to RIFLE. Crit Care Med 2007;35(8):1837-43; quiz 52
   PubMed Web of Science ®Google Scholar
• Piccinni P, Cruz DN, Gramaticopolo S, et al. Prospective multicenter study on epidemiology of acute kidney injury in the ICU: a critical care nephrology Italian collaborative effort (NEFROINT). Minerva Anestesiol 2011;77(11):1072-83
   PubMed Web of Science ®Google Scholar
• Levy MM, Artigas A, Phillips GS, et al. Outcomes of the Surviving Sepsis Campaign in intensive care units in the USA and Europe: a prospective cohort study. Lancet Infect Dis 2012;12(12):919-24
   PubMed Web of Science ®Google Scholar
• Morgera S, Schneider M, Neumayer HH. Long-term outcomes after acute kidney injury. Crit Care Med 2008;36(4 Suppl):S193-7
   PubMed Web of Science ®Google Scholar
• Ostermann M, Chang RW. Impact of different types of organ failure on outcome in intensive care unit patients with acute kidney injury. J Crit Care 2011;26(6):635; e1-35 e10
   PubMedGoogle Scholar
• Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16(1):31-41
   PubMed Web of Science ®Google Scholar
• Stevens LA, Claybon MA, Schmid CH, et al. Evaluation of the Chronic Kidney Disease Epidemiology Collaboration equation for estimating the glomerular filtration rate in multiple ethnicities. Kidney Int 2011;79(5):555-62
   PubMed Web of Science ®Google Scholar
• Kirwan CJ, Philips BJ, Macphee IA. Estimated glomerular filtration rate correlates poorly with four-hour creatinine clearance in critically ill patients with acute kidney injury. Crit Care Res Pract 2013;2013:406075
   PubMedGoogle Scholar
• Heimburger O, Stenvinkel P, Barany P. The enigma of decreased creatinine generation in acute kidney injury. Nephrol Dial Transplant 2012;27(11):3973-4
   PubMed Web of Science ®Google Scholar
• Pickering JW, Frampton CM, Walker RJ, et al. Four hour creatinine clearance is better than plasma creatinine for monitoring renal function in critically ill patients. Crit Care 2012;16(3):R107
   PubMed Web of Science ®Google Scholar
• Naderer O, Nafziger AN, Bertino JS Jr. Effects of moderate-dose versus high-dose trimethoprim on serum creatinine and creatinine clearance and adverse reactions. Antimicrob Agents Chemother 1997;41(11):2466-70
   PubMed Web of Science ®Google Scholar
• Wilson FP, Sheehan JM, Mariani LH, Berns JS. Creatinine generation is reduced in patients requiring continuous venovenous hemodialysis and independently predicts mortality. Nephrol Dial Transplant 2012;27(11):4088-94
   PubMed Web of Science ®Google Scholar
• Bougle A, Duranteau J. Pathophysiology of sepsis-induced acute kidney injury: the role of global renal blood flow and renal vascular resistance. Contrib Nephrol 2011;174:89-97
   PubMed Web of Science ®Google Scholar
• Langenberg C, Bellomo R, May C, et al. Renal blood flow in sepsis. Crit Care 2005;9(4):R363-74
   PubMed Web of Science ®Google Scholar
• Prowle JR, Ishikawa K, May CN, Bellomo R. Renal blood flow during acute renal failure in man. Blood Purif 2009;28(3):216-25
   PubMed Web of Science ®Google Scholar
• Brown D, Wagner CA. Molecular mechanisms of acid-base sensing by the kidney. J Am Soc Nephrol 2012;23(5):774-80
   PubMed Web of Science ®Google Scholar
• Verna EC, Wagener G. Renal interactions in liver dysfunction and failure. Curr Opin Crit Care 2013;19(2):133-41
   PubMed Web of Science ®Google Scholar
• Chateauvieux S, Grigorakaki C, Morceau F, et al. Erythropoietin, erythropoiesis and beyond. Biochem Pharmacol 2011;82(10):1291-303
   PubMed Web of Science ®Google Scholar
• Komers R. Renin inhibition in the treatment of diabetic kidney disease. Clin Sci (London, England 1979) 2013;124(9):553-66
   PubMed Web of Science ®Google Scholar
• Dusso A, Gonzalez EA, Martin KJ. Vitamin D in chronic kidney disease. Best Pract Res Clin Endocrinol Metab 2011;25(4):647-55
   PubMed Web of Science ®Google Scholar
• Gardiner SJ, Begg EJ. Pharmacogenetics, drug-metabolizing enzymes, and clinical practice. Pharmacol Rev 2006;58(3):521-90
   PubMed Web of Science ®Google Scholar
• Ricksten S-E, Bragadottir G, Redfors B. Renal oxygenation in clinical acute kidney injury. Crit Care 2013;17(2):221
   PubMed Web of Science ®Google Scholar
• Mohebbi N, Mihailova M, Wagner CA. The calcineurin inhibitor FK506 (tacrolimus) is associated with transient metabolic acidosis and altered expression of renal acid-base transport proteins. Am J Physiol Renal Physiol 2009;297(2):F499-509
   PubMed Web of Science ®Google Scholar
• Mårtensson J, Martling C-R, Bell M. Novel biomarkers of acute kidney injury and failure: clinical applicability. Br J Anaesth 2012;109(6):843-50
   PubMed Web of Science ®Google Scholar
• Ostermann M, Philips BJ, Forni LG. Clinical review: biomarkers of acute kidney injury: where are we now? Crit Care 2012;16(5):233
   PubMed Web of Science ®Google Scholar
• Lohr JW, Willsky GR, Acara MA. Renal drug metabolism. Pharmacol Rev 1998;50(1):107-42
   PubMed Web of Science ®Google Scholar
• Lash LH. Role of renal metabolism in risk to toxic chemicals. Environ Health Perspect 1994;102(Suppl 11):75-9
   PubMed Web of Science ®Google Scholar
• Phillips IR, Shephard EA. Flavin-containing monooxygenases: mutations, disease and drug response. Trends Pharmacol Sci 2008;29(6):294-301
   PubMed Web of Science ®Google Scholar
• Burckhardt G. Drug transport by organic anion transporters (OATs). Pharmcol Ther 2012;136(1):106-30
   PubMed Web of Science ®Google Scholar
• Naud J, Nolin TD, Leblond FA, Pichette V. Current understanding of drug disposition in kidney disease. J Clin Pharmacol 2012;52(1 Suppl):10S-22S
   PubMed Web of Science ®Google Scholar
• Wilkinson GR, Shand DG. Commentary: a physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975;18(4):377-90
   PubMed Web of Science ®Google Scholar
• Autschbach R, Falk V, Lange H, et al. Assessment of metabolic liver function and hepatic blood flow during cardiopulmonary bypass. Thorac Cardiovasc Surg 1996;44(2):76-80
   PubMed Web of Science ®Google Scholar
• Kirwan C, MacPhee I, Philips B. Using drug probes to monitor hepatic drug metabolism in critically ill patients: midazolam, a flawed but useful tool for clinical investigation of CYP3A activity? Expert Opin Drug Metab Toxicol 2010;6(6):761-71
   PubMed Web of Science ®Google Scholar
• Lane K, Dixon JJ, Macphee IA, Philips BJ. Renohepatic crosstalk: does acute kidney injury cause liver dysfunction? Nephrol Dial Transplant 2013;28(7):1634-47
   PubMed Web of Science ®Google Scholar
• Bains RK, Kovacevic M, Plaster CA, et al. Molecular diversity and population structure at the cytochrome P450 3A5 gene in Africa. BMC Genet 2013;14:34
   PubMed Web of Science ®Google Scholar
• Xie HG, Wood AJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004;5(3):243-72
   PubMed Web of Science ®Google Scholar
• Gertz M, Harrison A, Houston JB, Galetin A. Prediction of human intestinal first-pass metabolism of 25 CYP3A substrates from in vitro clearance and permeability data. Drug Metab Dispos 2010;38(7):1147-58
   PubMed Web of Science ®Google Scholar
• Lin JH, Chiba M, Baillie TA. Is the role of the small intestine in first-pass metabolism overemphasized? Pharmacol Rev 1999;51(2):135-58
   PubMed Web of Science ®Google Scholar
• Smith BS, Yogaratnam D, Levasseur-Franklin KE, et al. Introduction to drug pharmacokinetics in the critically ill patient. Chest 2012;141(5):1327-36
   PubMed Web of Science ®Google Scholar
• Boucher BA, Wood GC, Swanson JM. Pharmacokinetic changes in critical illness. Crit Care Clin 2006;22(2):255-71
   PubMed Web of Science ®Google Scholar
• Chou SY, Porush JG, Faubert PF. Renal medullary circulation: hormonal control. Kidney Int 1990;37(1):1-13
   PubMed Web of Science ®Google Scholar
• Saito H. Pathophysiological regulation of renal SLC22A organic ion transporters in acute kidney injury: pharmacological and toxicological implications. Pharmacol Ther 2010;125(1):79-91
   PubMed Web of Science ®Google Scholar
• Shimizu H, Bolati D, Adijiang A, et al. NF-kappaB plays an important role in indoxyl sulfate-induced cellular senescence, fibrotic gene expression, and inhibition of proliferation in proximal tubular cells. Am J Physiol Cell Physiol 2011;301(5):C1201-12
   PubMed Web of Science ®Google Scholar
• Ahn SY, Nigam SK. Toward a systems level understanding of organic anion and other multispecific drug transporters: a remote sensing and signaling hypothesis. Mol Pharmacol 2009;76(3):481-90
   PubMed Web of Science ®Google Scholar
• Vilay AM, Churchwell MD, Mueller BA. Clinical review: drug metabolism and nonrenal clearance in acute kidney injury. Crit Care 2008;12(6):235
   PubMed Web of Science ®Google Scholar
• Davenport A. The brain and the kidney–organ cross talk and interactions. Blood Purif 2008;26(6):526-36
   PubMed Web of Science ®Google Scholar
• Kirwan CJ, MacPhee IA, Lee T, et al. Acute kidney injury reduces the hepatic metabolism of midazolam in critically ill patients. Intensive Care Med 2012;38(1):76-84
   PubMed Web of Science ®Google Scholar
• Ronco C, Chionh CY, Haapio M, et al. The cardiorenal syndrome. Blood Purif 2009;27(1):114-26
   PubMed Web of Science ®Google Scholar
• Slack AJ, Wendon J. The liver and kidney in critically ill patients. Blood Purif 2009;28(2):124-34
   PubMed Web of Science ®Google Scholar
• Slack A, Yeoman A, Wendon J. Renal dysfunction in chronic liver disease. Crit Care 2010;14(2):214
   PubMed Web of Science ®Google Scholar
• Salerno F, Gerbes A, Ginès P, et al. Diagnosis, prevention and treatment of hepatorenal syndrome in cirrhosis. Postgrad Med J 2008;84(998):662-70
   PubMed Web of Science ®Google Scholar
• Kirwan CJ, Lee T, Holt DW, et al. Using midazolam to monitor changes in hepatic drug metabolism in critically ill patients. Intensive Care Med 2009;35(7):1271-5
   PubMed Web of Science ®Google Scholar
• Nolin TD, Naud J, Leblond FA, Pichette V. Emerging evidence of the impact of kidney disease on drug metabolism and transport. Clin Pharmacol Ther 2008;83(6):898-903
   PubMed Web of Science ®Google Scholar
• Huang ZH, Murakami T, Okochi A, et al. Expression and function of P-glycoprotein in rats with glycerol-induced acute renal failure. Eur J Pharmacol 2000;406(3):453-60
   PubMed Web of Science ®Google Scholar
• de Jonge H, de Loor H, Verbeke K, et al. In vivo CYP3A4 activity, CYP3A5 genotype, and hematocrit predict tacrolimus dose requirements and clearance in renal transplant patients. Clin Pharmacol Ther 2012;92(3):366-75
   PubMed Web of Science ®Google Scholar
• Michaud J, Dube P, Naud J, et al. Effects of serum from patients with chronic renal failure on rat hepatic cytochrome P450. Br J Pharmacol 2005;144(8):1067-77
   PubMed Web of Science ®Google Scholar
• Michaud J, Naud J, Chouinard J, et al. Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure. J Am Soc Nephrol 2006;17(11):3041-8
   Web of Science ®Google Scholar
• Michaud J, Nolin TD, Naud J, et al. Effect of hemodialysis on hepatic cytochrome P450 functional expression. J Pharmacol Sci 2008;108(2):157-63
   PubMed Web of Science ®Google Scholar
• Velenosi TJ, Fu AY, Luo S, et al. Down-regulation of hepatic CYP3A and CYP2C mediated metabolism in rats with moderate chronic kidney disease. Drug Metab Dispos 2012;40(8):1508-14
   PubMed Web of Science ®Google Scholar
• Dreisbach AW, Lertora JJ. The effect of chronic renal failure on drug metabolism and transport. Expert Opin Drug Metab Toxicol 2008;4(8):1065-74
   PubMed Web of Science ®Google Scholar
• Okabe H, Hasunuma M, Hashimoto Y. The hepatic and intestinal metabolic activities of P450 in rats with surgery- and drug-induced renal dysfunction. Pharm Res 2003;20(10):1591-4
   PubMed Web of Science ®Google Scholar
• Okabe H, Higashi T, Ohta T, Hashimoto Y. Intestinal absorption and hepatic extraction of propranolol and metoprolol in rats with bilateral ureteral ligation. Biol Pharm Bull 2004;27(9):1422-7
   PubMed Web of Science ®Google Scholar
• Okabe H, Yano I, Hashimoto Y, et al. Evaluation of increased bioavailability of tacrolimus in rats with experimental renal dysfunction. J Pharm Pharmacol 2002;54(1):65-70
   PubMed Web of Science ®Google Scholar
• Lee AK, Lee JH, Kwon JW, et al. Pharmacokinetics of clarithromycin in rats with acute renal failure induced by uranyl nitrate. Biopharm Drug Dispos 2004;25(6):273-82
   PubMed Web of Science ®Google Scholar
• Spapen H. Liver perfusion in sepsis, septic shock, and multiorgan failure. Anat Rec 2008;291(6):714-20
   Google Scholar
• Soni N. Wonderful albumin? BMJ 1995;310(6984):887-8
   PubMed Web of Science ®Google Scholar
• Kragh-Hansen U. Molecular and practical aspects of the enzymatic properties of human serum albumin and of albumin-ligand complexes. Biochim Biophys Acta 2013[ Epub ahead of print]
   Web of Science ®Google Scholar
• Niwa T. Update of uremic toxin research by mass spectrometry. Mass Spectrom Rev 2011;30(3):510-21
   PubMed Web of Science ®Google Scholar
• Gurley BJ, Barone GW, Yamashita K, et al. Extrahepatic ischemia-reperfusion injury reduces hepatic oxidative drug metabolism as determined by serial antipyrine clearance. Pharm Res 1997;14(1):67-72
   PubMed Web of Science ®Google Scholar
• Choi JS, Lee JH, Burm JP. Pharmacokinetics of diltiazem and its major metabolite, deacetyidiltiazem after oral administration of diltiazem in mild and medium folate-induced renal failure rabbits. Arch Pharm Res 2001;24(4):333-7
   PubMed Web of Science ®Google Scholar
• Izuwa Y, Kusaba J, Horiuchi M, et al. Comparative study of increased plasma quinidine concentration in rats with glycerol- and cisplatin-induced acute renal failure. Drug Metab Pharmacokinet 2009;24(5):451-7
   PubMed Web of Science ®Google Scholar
• Yoshitani T, Yagi H, Inotsume N, Yasuhara M. Effect of experimental renal failure on the pharmacokinetics of losartan in rats. Biol Pharm Bull 2002;25(8):1077-83
   PubMed Web of Science ®Google Scholar
• Venkatesh P, Harisudhan T, Choudhury H, et al. Pharmacokinetics of etoposide in rats with uranyl nitrate (UN)-induced acute renal failure (ARF): optimization of the duration of UN dosing. Eur J Drug Metab Pharmacokinet 2007;32(4):189-96
   PubMed Web of Science ®Google Scholar
• Karim MS, Wood RF, Dawnay AB, Fulton PA. The effect of renal ischemia on cyclosporine clearance in rabbits. Transplantation 1990;49(3):500-2
   PubMed Web of Science ®Google Scholar
• Choi YH, Lee YS, Kim TK, et al. Faster clearance of mirodenafil in rats with acute renal failure induced by uranyl nitrate: contribution of increased protein expression of hepatic CYP3A1 and intestinal CYP1A1 and 3A1/2. J Pharm Pharmacol 2009;61(10):1325-32
   PubMed Web of Science ®Google Scholar
• Yu SY, Chung HC, Kim EJ, et al. Effects of acute renal failure induced by uranyl nitrate on the pharmacokinetics of intravenous theophylline in rats: the role of CYP2E1 induction in 1,3-dimethyluric acid formation. J Pharm Pharmacol 2002;54(12):1687-92
   PubMed Web of Science ®Google Scholar
• Srinivas NR. Pharmacokinetics of tolbutamide in acute renal failure induced by glycerol: speculative thoughts and perspectives. Drug Metab Pharmacokinet 2011;26(2):216-17
   PubMed Web of Science ®Google Scholar
• Tanabe H, Taira S, Taguchi M, Hashimoto Y. Pharmacokinetics and hepatic extraction of metoprolol in rats with glycerol-induced acute renal failure. Biol Pharm Bull 2007;30(3):552-5
   PubMed Web of Science ®Google Scholar
• Shibata N, Inoue Y, Fukumoto K, et al. Evaluation of factors to decrease bioavailability of cyclosporin A in rats with gentamicin-induced acute renal failure. Biol Pharm Bull 2004;27(3):384-91
   PubMed Web of Science ®Google Scholar
• Moon YJ, Lee AK, Chung HC, et al. Effects of acute renal failure on the pharmacokinetics of chlorzoxazone in rats. Drug Metab Dispos 2003;31(6):776-84
   PubMed Web of Science ®Google Scholar
• Chung HC, Kim SH, Lee MG, Kim SG. Increase in urea in conjunction with L-arginine metabolism in the liver leads to induction of cytochrome P450 2E1 (CYP2E1): the role of urea in CYP2E1 induction by acute renal failure. Drug Metab Dispos 2002;30(6):739-46
   PubMed Web of Science ®Google Scholar
• Muntane-Relat J, Ourlin JC, Domergue J, Maurel P. Differential effects of cytokines on the inducible expression of CYP1A1, CYP1A2, and CYP3A4 in human hepatocytes in primary culture. Hepatology 1995;22(4 Pt 1):1143-53
   PubMed Web of Science ®Google Scholar
• Morgan ET, Goralski KB, Piquette-Miller M, et al. Regulation of drug-metabolizing enzymes and transporters in infection, inflammation, and cancer. Drug Metab Dispos 2008;36(2):205-16
   PubMed Web of Science ®Google Scholar
• Klein CL, Hoke TS, Fang WF, et al. Interleukin-6 mediates lung injury following ischemic acute kidney injury or bilateral nephrectomy. Kidney Int 2008;74(7):901-9
   PubMed Web of Science ®Google Scholar
• Tracz MJ, Juncos JP, Croatt AJ, et al. Deficiency of heme oxygenase-1 impairs renal hemodynamics and exaggerates systemic inflammatory responses to renal ischemia. Kidney Int 2007;72(9):1073-80
   PubMed Web of Science ®Google Scholar
• Castell JV, Gomez-Lechon MJ, David M, et al. Interleukin-6 is the major regulator of acute phase protein synthesis in adult human hepatocytes. FEBS Lett 1989;242(2):237-9
   PubMed Web of Science ®Google Scholar
• Abdel-Razzak Z, Loyer P, Fautrel A, et al. Cytokines down-regulate expression of major cytochrome P-450 enzymes in adult human hepatocytes in primary culture. Mol Pharmacol 1993;44(4):707-15
   PubMed Web of Science ®Google Scholar
• Pascussi JM, Gerbal-Chaloin S, Pichard-Garcia L, et al. Interleukin-6 negatively regulates the expression of pregnane X receptor and constitutively activated receptor in primary human hepatocytes. Biochem Biophys Res Commun 2000;274(3):707-13
   PubMed Web of Science ®Google Scholar
• Liu KD. Impact of acute kidney injury on lung injury. Am J Physiol Lung Cell Mol Physiol 2009;296(1):L1-2
   PubMed Web of Science ®Google Scholar
• Liu KD, Altmann C, Smits G, et al. Serum interleukin-6 and interleukin-8 are early biomarkers of acute kidney injury and predict prolonged mechanical ventilation in children undergoing cardiac surgery: a case-control study. Crit Care 2009;13(4):R104
   PubMedGoogle Scholar
• Chawla LS, Seneff MG, Nelson DR, et al. Elevated plasma concentrations of IL-6 and elevated APACHE II score predict acute kidney injury in patients with severe sepsis. Clin J Am Soc Nephrol 2007;2(1):22-30
   PubMed Web of Science ®Google Scholar
• Simmons EM, Himmelfarb J, Sezer MT, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int 2004;65(4):1357-65
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Chrousos GP, Weber JS. Recombinant interleukin-6 activates the hypothalamic-pituitary-adrenal axis in humans. J Clin Endocrinol Metab 1993;77(6):1690-4
   PubMed Web of Science ®Google Scholar
• Mastorakos G, Weber JS, Magiakou MA, et al. Hypothalamic-pituitary-adrenal axis activation and stimulation of systemic vasopressin secretion by recombinant interleukin-6 in humans: potential implications for the syndrome of inappropriate vasopressin secretion. J Clin Endocrinol Metab 1994;79(4):934-9
   PubMed Web of Science ®Google Scholar
• Furuta T, Suzuki A, Mori C, et al. Evidence for the validity of cortisol 6β-hydroxylation clearance as a new index for in vivo cytochrome P450 3A phenotyping in humans. Drug Metab Dispos 2003;31(11):1283-7
   PubMed Web of Science ®Google Scholar
• Zgoda-Pols JR, Chowdhury S, Wirth M, et al. Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol 2011;255(1):48-56
   PubMed Web of Science ®Google Scholar
• Schroeder JC, Dinatale BC, Murray IA, et al. The uremic toxin 3-indoxyl sulfate is a potent endogenous agonist for the human aryl hydrocarbon receptor. Biochemistry 2010;49(2):393-400
   PubMed Web of Science ®Google Scholar
• Hanada K, Ogawa R, Son K, et al. Effects of indoxylsulfate on the in vitro hepatic metabolism of various compounds using human liver microsomes and hepatocytes. Nephron Physiol 2006;103(4):p179-86
   PubMed Web of Science ®Google Scholar
• Lim CF, Bernard BF, de Jong M, et al. A furan fatty acid and indoxyl sulfate are the putative inhibitors of thyroxine hepatocyte transport in uremia. J Clin Endocrinol Metab 1993;76(2):318-24
   PubMed Web of Science ®Google Scholar
• Odamaki M, Kato A, Kumagai H, Hishida A. Counter-regulatory effects of procalcitonin and indoxyl sulphate on net albumin secretion by cultured rat hepatocytes. Nephrol Dial Transplant 2004;19(4):797-804
   PubMed Web of Science ®Google Scholar
• Vaziri ND. CKD impairs barrier function and alters microbial flora of the intestine: a major link to inflammation and uremic toxicity. Curr Opin Nephrol Hypertens 2012;21(6):587-92
   PubMed Web of Science ®Google Scholar
• Vaziri ND, Yuan J, Norris K. Role of urea in intestinal barrier dysfunction and disruption of epithelial tight junction in chronic kidney disease. Am J Nephrol 2013;37(1):1-6
   PubMed Web of Science ®Google Scholar
• Ostermann M, Chang RW. Correlation between parameters at initiation of renal replacement therapy and outcome in patients with acute kidney injury. Crit Care 2009;13(6):R175
   PubMedGoogle Scholar
• Kopple JD, Kalantar-Zadeh K, Mehrotra R. Risks of chronic metabolic acidosis in patients with chronic kidney disease. Kidney Int Suppl 2005(95):S21-7
   Google Scholar
• Kalantar-Zadeh K, Mehrotra R, Fouque D, Kopple JD. Metabolic acidosis and malnutrition-inflammation complex syndrome in chronic renal failure. Semin Dial 2004;17(6):455-65
   PubMed Web of Science ®Google Scholar
• Kleger GR, Turgay M, Imoberdorf R, et al. Acute metabolic acidosis decreases muscle protein synthesis but not albumin synthesis in humans. Am J kidney Dis 2001;38(6):1199-207
   PubMed Web of Science ®Google Scholar
• Scatena R, Bottoni P, Botta G, et al. The role of mitochondria in pharmacotoxicology: a reevaluation of an old, newly emerging topic. Am J Physiol Cell Physiol 2007;293(1):C12-21
   PubMed Web of Science ®Google Scholar
• Sun J, Shannon M, Ando Y, et al. Serum metabolomic profiles from patients with acute kidney injury: a pilot study. J Chromatogr B. Analyt Technol Biomed Life Sci 2012;893-894:107-13
   PubMed Web of Science ®Google Scholar
• Park SW, Chen SW, Kim M, et al. Cytokines induce small intestine and liver injury after renal ischemia or nephrectomy. Lab Invest 2011;91(1):63-84
   PubMed Web of Science ®Google Scholar
• Andres-Hernando A, Dursun B, Altmann C, et al. Cytokine production increases and cytokine clearance decreases in mice with bilateral nephrectomy. Nephrol Dial Transplant 2012;27(12):4339-47
   PubMed Web of Science ®Google Scholar
• Park SW, Kim M, Kim JY, et al. Paneth cell-mediated multiorgan dysfunction after acute kidney injury. J Immunol 2012;189(11):5421-33
   PubMed Web of Science ®Google Scholar
• Andres-Hernando A, Altmann C, Ahuja N, et al. Splenectomy exacerbates lung injury after ischemic acute kidney injury in mice. Am J Physiol Renal Physiol 2011;301(4):F907-16
   PubMed Web of Science ®Google Scholar
• Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int 2012;32(9):2601-4
   PubMed Web of Science ®Google Scholar
• Rodvold KA. Clinical pharmacokinetics of clarithromycin. Clin Pharmacokinet 1999;37(5):385-98
   PubMed Web of Science ®Google Scholar
• Gomez G, Alvarez ML, Errasti P, et al. Acute tacrolimus nephrotoxicity in renal transplant patients treated with clarithromycin. Transplant Proc 1999;31(6):2250-1
   PubMed Web of Science ®Google Scholar
• Pereira JM, Paiva JA. Antimicrobial drug interactions in the critically ill patients. Curr Clin Pharmacol 2013;8(1):25-38
   PubMedGoogle Scholar
• Loh GW, Mabasa VH, Ensom MH. Therapeutic drug monitoring in the neurocritical care unit. Curr Opin Crit Care 2010;16(2):128-35
   PubMed Web of Science ®Google Scholar